Beyondspring Inc
NASDAQ:BYSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beyondspring Inc
Net Issuance of Common Stock
Beyondspring Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beyondspring Inc
NASDAQ:BYSI
|
Net Issuance of Common Stock
$2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
-19%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$808m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$1.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
17%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$2.8B
|
CAGR 3-Years
-71%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Beyondspring Inc
Glance View
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
See Also
What is Beyondspring Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
2m
USD
Based on the financial report for Dec 31, 2025, Beyondspring Inc's Net Issuance of Common Stock amounts to 2m USD.
What is Beyondspring Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-19%
Over the last year, the Net Issuance of Common Stock growth was -33%. The average annual Net Issuance of Common Stock growth rates for Beyondspring Inc have been -26% over the past three years , -56% over the past five years , and -19% over the past ten years .
